A study presented at the European Renal Association-European Dialysis and Transplant Association meeting found patients with type 2 diabetes and nephropathy who received atrasentan attained improvements in albuminuria and bad cholesterol and triglyceride levels at 12 weeks compared with those who took a placebo. However, the findings merit further and longer-term assessment to see whether the drug would be beneficial, a researcher said.
Drug curbs albuminuria, cholesterol in type 2 diabetes, nephropathy
SmartBrief Job Listings for Health Care
|Vice President - Government Products||
Health Alliance Plan
|Director, Compliance - Health Plan Privacy & Security||
|Chief Medical Officer||
VANDERBILT HEALTH AFFILIATE NETWORK
|Commercial Health Insurance Strategist__Job #52-14||
American Academy of Family Physicians
|Manager of Payer Relations||
Pharmacy Quality Solutions, Inc.